# UNCY catalysts: Unicycive Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/uncy/catalysts

> Unicycive Therapeutics, Inc. (UNCY) has no upcoming catalysts in this calendar. The latest recorded is the Unicycive Therapeutics, Inc. earnings report, August 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Unicycive Therapeutics, Inc. |
| Ticker | UNCY (Nasdaq) |
| SEC CIK | 1766140 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/uncy |

## Cash runway

Cash $61.4M as of 2026-06-30; quarterly burn $7.6M; about 24.2 months of runway at that rate (XBRL company facts, accession 0001213900-26-088013).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 3, 2024 | [Oxylanthanum NDA/BLA submission](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | hyperphosphatemia in patients with chronic kidney disease | completed | "On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm)) |
| November 11, 2024 | [Oxylanthanum NDA/BLA acceptance](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed | "On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm)) |
| November 13, 2024 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "13, 2024 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/ea022088901ex99-1_unicycive.htm)) |
| March 31, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| March 31, 2025 | [UNI-494 NDA/BLA acceptance](https://sec-api.dev/pdufa/uni-494) | UNCY | hyperphosphatemia in patients with CKD | completed | "Announced the acceptance of the New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| May 14, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| Jun 2025 | [UNI-494 complete response letter (CRL)](https://sec-api.dev/pdufa/uni-494) | UNCY |  | completed, complete response letter | "The 2026 CRL cited the same third-party manufacturing deficiencies identified in a previous CRL issued in June 2025 to the initial NDA submission, as a result of the FDA not having conducted the reinspection of the original third-party manufacturing vendor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026104314/ea030696701ex99-1.htm)) |
| June 27, 2025 | [Nda218607 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218607) | UNCY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218607_20250627.pdf%22)) |
| June 28, 2025 | [UNI-494 PDUFA date](https://sec-api.dev/pdufa/uni-494) | UNCY |  | scheduled | "The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for OLC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| June 28, 2025 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed, complete response letter | "- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| June 30, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | Hyperphosphatemia in Patients with Chronic Kidney Disease | completed, complete response letter | "Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm)) |
| August 14, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/ea025316301ex99-1_unicy.htm)) |
| late 2025 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed, complete response letter | "- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| October 28, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | kidney disease | completed, complete response letter | "On October 28, 2025, we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| November 12, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/ea026522701ex99-1_unicycive.htm)) |
| Dec 2025 | [Oxylanthanum NDA/BLA submission](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed | "Following receipt of the official meeting minutes from the Type A meeting and engaging in discussions with our third-party manufacturing vendor, we resubmitted our NDA to the FDA in December 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| Jan 2026 | [UNI-494 NDA/BLA acceptance](https://sec-api.dev/pdufa/uni-494) | UNCY | hyperphosphatemia in patients with CKD | completed | "January 2026, the Company announced the FDA accepted the resubmission of its NDA for OLC, an investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with CKD on dialysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm)) |
| March 30, 2026 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea028394201ex99-1.htm)) |
| May 12, 2026 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm)) |
| June 29, 2026 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | scheduled | "Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm)) |
| June 29, 2026 | [Nda218607 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218607) | UNCY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218607_20260629.pdf%22)) |
| June 30, 2026 | [Unicycive Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed, complete response letter | "On June 30, 2026, we announced that we received a CRL from the FDA regarding the resubmitted NDA for OLC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| August 12, 2026 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea030169901ex99-1.htm)) |

## Drugs

- [Nda218607](https://sec-api.dev/pdufa/nda218607): 
- [Oxylanthanum](https://sec-api.dev/pdufa/oxylanthanum): hyperphosphatemia in patients with chronic kidney disease, kidney disease
- [UNI-494](https://sec-api.dev/pdufa/uni-494): hyperphosphatemia in patients with ckd

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/uncy/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "UNCY catalysts: Unicycive Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/uncy/catalysts

```bibtex
@misc{secapidev_companies_uncy_catalysts_20261116,
  title        = {UNCY catalysts: Unicycive Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/uncy/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_uncy_catalysts_20261116","title":"UNCY catalysts: Unicycive Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/uncy/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
